Screening and treatment of retinopathy of prematurity: current status, problems and prospects in China

( views:161, downloads:0 )
Author:
ZHAO Pei-quan(Department of Ophthalmology, Xinghua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China)
FEI Ping(Department of Ophthalmology, Xinghua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China)
Journal Title:
Chinese Journal of Ocular Fundus Diseases
Issue:
Volume 28, Issue 01, 2012
DOI:
10.3760/cma.i.issn.1005-1015.2012.01.002
Key Word:
Retinopathy of prematurity/diagnosis;Retinopathy of prematurity/drug therapy;Laser coagulation;Cryotherapy;Editorial

Abstract: Early detection and timely treatment hold the key to cure retinopathy of prematurity (ROP).ROP screening is carried out unevenly in China.Examination equipments and personnel experiences are the major factors to constraint ROP screening.In addition to strengthening personnel training,it is necessary to establish a standard guideline and pipeline for ROP consultation and referral. Laser photocoagulation and cryotherapy are the first options for the threshold ROP and Type 1 pre-threshold ROP.Scleral buckling or vitrectomy is needed for advanced ROP when retinal detachment occurs. The clinical efficacy of intravitreal injection of bevacizumab (an anti-vascular endothelial growth factor monoclonal antibody) for severe ROP is encouraging,but needs further verification.Genetic interference and stem cell therapy will be the prosperous futures in the treatment of ROP.The screening and treatment of ROP in China is becoming more common and improved,but it is still a long way to go considering the huge population of China.

  • [1]Cryotherapy for Retinopathy of Prematurity Cooperative Group.Multicenter trial of cryotherapy for retinopathy of prematurity:preliminary results.Arch Ophthalmol,1988,106:471-479.
  • [2]Cryotherapy for Retinopathy of Prematurity Cooperative Group.Multicenter trial of cryotherapy for retinopathy of prematurity:three-month outcome.Arch Ophthalmol,1990,108:195-204.
  • [3]Cryotherapy for Retinopathy of Prematurity Cooperative Group.Multicenter trial of cryotherapy for retinopathy of prematurity:3 1/2-year outcome--structure and function.Arch Ophthalmol,1993,111:339-344.
  • [4]Cryotherapy for Retinopathy of Prematurity Cooperative Group.Multicenter trial of cryotherapy for retinopathy of prematurity:snellen visual acuity and structural outcome at 5 1/2 years after randomization.Arch Ophthalmol,1996,114:417-424.
  • [5]The Committee for the Classification of Retinopathy of Prematurity.An international classification of retinopathy of prematurity.Arch Ophthalmol,1984,102:1130-1134.
  • [6]Early Treatment for Retinopathy of Prematurity Cooperative Group.Revised indications for the treatment of retinopathy of prematurity:results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol,2003,121:1684-1694.
  • [7]Sanghi G,Dogra MR,Vinekar A,et al. Frequency-doubled Nd:YAG (532 nm green) versus diode laser (810 nm) in treatment of retinopathy of prematurity.Br J Ophthalmol,2009,94:1264-1265.
  • [8]单海冬,赵培泉,黄欣,等.经双目间接检眼镜激光光凝治疗严重早产儿视网膜病变.中华眼底病杂志,2008,24:13-16.
  • [9]尹虹,黎晓新,姜燕荣,等.极低体重早产儿视网膜病变的临床研究.中华眼底病杂志,2005,21:275-277.
  • [10]张国明,曾键,黄丽娜,等.广角数码儿童视网膜成像系统引导下激光光凝治疗早产儿视网膜病变.中华眼底病杂志,2008,24:17-19.
  • [11]赵培泉,单海冬,程朝晖,等.阈值前病变1型和阈值期早产儿视网膜病变的激光和冷冻治疗.中华眼底病杂志,2005,21:278-281.
  • [12]Trese MT. Scleral buckling for retinopathy of prematurity.Ophthalmology,1994,101:23-26.
  • [13]黄欣,赵培泉,单海冬,等.冷凝和巩膜外环扎治疗4期早产儿视网膜病变五例.中华眼底病杂志,2005,21:331-332.
  • [14]Flynn JT,Bancalari E,Bachynski BN,et al.Retinopathy of prematurity: diagnosis, severity, and natural history.Ophthalmology,1987,94:620-629.
  • [15]Chuang YC,Yang CM.Scleral buckling for stage 4 retinopathy of prematurity.Ophthalmic Surg Lasers,2000,31:374-379.
  • [16]Greven C, Tasman W. Scleral buckling in stages 4B and 5 retinopathy of prematurity.Ophthalmology,1990,97:817-820.
  • [17]Hinz BJ,de Juan E Jr,Repka MX.Scleral buckling surgery for active stage 4A retinopathy of prematurity. Ophthalmology,1998,105:1827-1830.
  • [18]Capone A Jr,Trese MT. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments.Ophthalmology,2001,108:2068-2070.
  • [19]Hubbard GB 3rd, Cherwick DH, Burian G. Lens-sparing vitrectomy for stage 4 retinopathy of prematurity.Ophthalmology,2004,111:2274-2277.
  • [20]Lakhanpal RR,Davis GH,Sun RL,et al.Lens clarity after 3-port lens-sparing vitrectomy in stage 4A and 4B retinal detachments secondary to retinopathy of prematurity. Arch Ophthalmol,2006,124:20-23.
  • [21]Prenner JL,Capone A Jr,Trese MT. Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity.Ophthalmology,2004,111:2271-2273.
  • [22]Hanneken A, Baird A. Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid.Invest Ophthalmol Vis Sci,1995,36:1192-1196.
  • [23]黄欣,赵培泉,单海冬,等.闭合式三切口玻璃体视网膜手术治疗4期和5期早产儿视网膜病变.中华眼底病杂志,2008,24:9-12.
  • [24]Fuchino Y,Hayashi H,Kono T,et al.Long-term follow up of visual acuity in eyes with stage 5 retinopathy of prematurity after closed vitrectomy.Am J Ophthalmol,1995,120:308-316.
  • [25]Hirose T,Katsumi O,Mehta MC,et al. Vision in stage 5 retinopathy of prematurity after retinal reattachment by open-sky vitrectomy.Arch Ophthalmol,1993,111:345-349.
  • [26]Quinn GE,Dobson V,Barr CC,et al.Visual acuity of eyes after vitrectomy for retinopathy of prematurity:follow-up at 5 1/2 years.Ophthalmology,1996,103:595-600.
  • [27]Trese MT. Visual results and prognostic factors for vision following surgery for stage V retinopathy of prematurity.Ophthalmology,1986,93:574-579.
  • [28]Trese MT,Droste PJ. Long-term postoperative results of a consecutive series of stages 4 and 5 retinopathy of prematurity.Ophthalmology,1998,105:992-997.
  • [29]Lakhanpal RR,Fortun JA,Chan-Kai B,et al.Lensectomy and vitrectomy with and without intravitreal triamcinolone acetonide for vascularly active stage 5 retinal detachments in retinopathy of prematurity.Retina,2006,26:736-740.
  • [30]Gandorfer A. Microplasmin-assisted vitrectomy. Dev Ophthalmol,2009,44:26-30.
  • [31]Wu WC,Drenser KA,Lai M,et al.Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity.Retina,2008,28:75-80.
  • [32]尹虹,黎晓新.早产儿视网膜病变全视网膜脱离的玻璃体视网膜手术治疗预后.中华眼底病杂志,2008,24:5-8.
  • [33]Pierce EA,Avery RL,Foley ED,et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.Proc Natl Acad Sci USA,1995,92:905-909.
  • [34]Presta LG,Chen H,O'Connor SJ,et al.Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res,1997,57:4593-4599.
  • [35]Mintz-Hittner HA,Kennedy KA,Chuang AZ,et al.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.N Engl J Med,2011,364:603-615.
  • [36]Atchaneeyasakul LO, Trinavarat A. Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity.J Perinatol,2010,30:497-499.
  • [37]Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.Graefes Arch Clin Exp Ophthalmol,2008,246:1061-1063.
  • [38]Wu L,Martinez-Castellanos MA,Quiroz-Mercado H,et al.Twelve-month safety of intravitreal injections of bevacizumab (Avastin):results of the Pan-American Collaborative Retina Study Group (PACORES).Graefes Arch Clin Exp Ophthalmol,2008,246:81-87.
  • [39]Gilbert CE,Zin A,Darlow B.Bevacizumab for retinopathy of prematurity.N Engl J Med,2011,364:2359-2360.
  • [40]Gole GA,Camuglia JE,Ells AL.Bevacizumab for retinopathy of prematurity.N Engl J Med,2011,364:2360-2361.
  • [41]Good WV,Palmer EA. Bevacizumab for retinopathy of prematurity.N Engl J Med,2011,364:2359.
  • [42]Sato T,Wada K,Arahori H,et al.Serum concentrations of bevacizumab.(Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity [J/OL]. Am J Ophthalmol,2011,148:E1[2011-09-17]. http://www,ncbi.nlm.nih. gov/pubmed/21930258.[published online ahead of print].
  • [43]Voelkel NF,Vandivier RW,Tuder RM.Vascular endothelial growth factor in the lung.Am J Physiol Lung Cell Mol Physiol,2006,290:209-221.
  • [44]Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.Ophthalmic Surg Lasers Imaging,2007,38:233-237.
  • [45]Wutthiworawong B,Thitiratsanont U,Saovaprut C,et al.Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).J Med Assoc Thai,2011,94Suppl 3:15-21.
  • [46]Green WR, Key SN 3rd. Senile macular degeneration: a histopathologic study.Trans Am Ophthalmol Soc,1977,75:180-254.
  • [47]Hikino S,Ihara K,Yamamoto J,et al.Physical growth and retinopathy in preterm infants:involvement of IGF-I and GH.Pediatr Res,2001,50:732-736.
  • [48]Smith LE,Shen W,Perruzzi C,et al.Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.Nat Med,1999,5:1390-1395.
  • [49]Robinson GS,Pierce EA,Rook SL,et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.Proc Natl Acad Sci USA,1996,93:4851-4856.
  • [50]Mori K,Duh E,Gehlbach P,et al.Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol,2001,188:253-263.
  • [51]Zhao H,Sun X. Angiopoitetins and neovacularization. Int J Ophthalmol,2004,4:887-890.
  • [52]宋哲,黎晓新.腺伴随病毒载体介导Kringle5基因治疗早产儿视网膜病变大鼠视网膜新生血管.中华眼底病杂志,2005,21:288-291.
  • [53]Ivanova NB,Dimos JT,Schaniel C,et al.A stem cell molecular signature.Science,2002,298:601-604.
  • [54]Asahara T,Murohara T,Sullivan A,et al.Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997,275:964-967.
  • [55]Otani A,Kinder K,Ewalt K,et al.Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis.Nat Med,2002,8:1004-1010.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn